Supervisory Board
| Michiel de Haan (Chairman) Aescap Venture | |
|---|---|
| Michiel de Haan became chairman of Avantium's Supervisory Board in July 2010. He has been active in venture capital since 1980 when he founded Atlas Venture, a European-American venture capital firm that has been involved in more than 300 venture backed companies. Currently he is General Partner of Aescap Venture that he founded in 2005. Aescap invests in emerging Life Science companies in Europe. Michiel is past chairman of the European Venture Capital Association ( EVCA ) and co-founder of the European Venture Philanthropy Association ( EVPA ). |
 |
| Robert James DFJ Esprit | |
| Rob James manages DFJEsprit's portfolio of healthcare and medical technology investments. Since joining Esprit in 1998, he has been involved in a number of successful transactions including the exits from Oxford Biomedica and DNA Research Innovations. Rob manages DFJEsprit's investments in Oxford Immunotec, Kiadis Pharmaceuticals and Avantium. Prior to his time in venture capital, Robert worked for seven years commercialising cancer therapeutics and diagnostics arising from the research conducted by Cancer Research UK. He was responsible for licensing Temodal to Schering Plough (generating annual sales in excess of $600m) and Trovax to Oxford Biomedica. Rob graduated with a genetics degree from Sheffield University and a biochemistry PhD from the University of London. He has also served on the BVCA Technology Committee for four years. |  |
| Claude Stoufs Capricorn Cleantech | |
| Claude Stoufs holds a Master of Science degree in Chemistry. He is a graduate in Business Administration and a graduate in International Trade from the University of Brussels. He joined Akzo/Fabelta in 1974 and was subsequently recruited by PA Technology end-1980 and became Senior Consultant in charge of the technology strategy consulting practice. After 5 years with PA, he worked at Occidental Petroleum where he held the dual responsibility of business development for the European chemical division and M&A in the European market. Claude joined FMC Corp. to lead the M&A activities in Europe. He came to Capricorn Venture Partners as Senior Investment Manager in 2000. His contribution to the funds advised by Capricorn is mainly in the areas of biotechnology, healthcare, advanced materials and cleantech. Claude serves or has served at the Board of Directors of BioAlliance, Elbion / 4AZA, TiGenix, UroGene, FlandersBio vzw, Fluxome, Alaska Food Diagnostics, AK Diagnostics Europe, Avantium, FRX Polymers, Capricorn Venture Fund II and Capricorn Cleantech Fund. |
 |
| Dr. Jan van der Eijk | |
| Dr. Jan van der Eijk was the first Group Chief Technology Officer of Royal Dutch Shell and his 30-year career with this company covered a wide range of research, technology and business management positions in the Netherlands, the UK and the USA. He has a profound understanding of the business value of technology differentiation and hands on experience in developing and marketing of new chemicals and refining processes and products. Additionally, he has a strong track record of adding value to chemical companies through active participation in Supervisory Boards. |  |